Zydus Lifesciences Secures USFDA Approval for Imaging Agent with Market Exclusivity

Zydus Lifesciences has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Indocyanine Green for Injection, 25 mg/vial. The US health regulator has designated this as a Competitive Generic Therapy (CGT), granting the company 180 days of market exclusivity in the United States, starting from the commencement of commercial marketing.

Reader Takeaway: Success in complex injectables with exclusivity; strong market growth offers revenue opportunity.

What just happened

The company has obtained the crucial USFDA approval for Indocyanine Green for Injection. This approval comes with a significant competitive advantage: 180 days of market exclusivity due to its CGT designation.

Why this matters

This approval allows Zydus Lifesciences to enter a potentially lucrative market segment. The 180-day exclusivity period provides a window to establish market share before broader competition emerges. The reference listed drug has a significant market presence, with annual sales of USD 125.8 million and robust growth of 61.0% (MAT June-2026).

The backstory

Indocyanine Green is an optical imaging agent used in surgeries to visualize vessels, blood flow, and tissue perfusion. Zydus Lifesciences plans to manufacture this product at its facility in Jarod, Gujarat, which is approved by the USFDA. The product will be marketed in the US by Zydus Pharmaceuticals (USA) Inc.

What changes now

The company can now plan its commercial launch strategy to leverage the 180-day exclusivity. This development strengthens Zydus's position in the complex injectable and imaging product sector.

Risks to watch

Investors should be aware of potential risks, including standard regulatory and operational challenges in the US generics market. Specific safety warnings highlight contraindications for hypersensitivity to indocyanine green and sodium iodide, with reported adverse reactions like hypersensitivity and anaphylaxis. Commercial success also depends on competitive intensity, pricing pressures, and supply chain stability.

Peer comparison

While specific peer product approvals aren't detailed in the filing, Zydus's overall USFDA portfolio includes 445 approvals and 513 ANDA filings as of June 30, 2026, indicating a consistent track record in developing and filing generic products.

Context metrics

US Annual Sales (Brand): USD 125.8 million (MAT June-2026)
US Annual Sales Growth (Brand): 61.0% (MAT June-2026)
US Annual Volume (Brand): 0.64 million units (MAT June-2026)
US Annual Volume Growth (Brand): 27.1% (MAT June-2026)
Total USFDA Approvals: 445 (As on 30-June-2026)
Total ANDA Filings: 513 (As on 30-June-2026)

What to track next

Investors should monitor the company's commercialization strategy, the exact launch date to trigger exclusivity, and sales performance during the exclusivity period. The ability to maintain momentum in complex product development will be key.